Quotient Sciences acquires Pharmaterials

15 November 2017

London, UK – GHO Capital, the European specialist investor in healthcare, acknowledges the announcement from its portfolio company Quotient Sciences regarding its acquisition of Pharmaterials, a UK-based Contract Development and Manufacturing Organisation.

Quotient Sciences (“Quotient”), the early phase drug development services provider, announced that it has acquired Pharmaterials, a contract development and manufacturing organisation (CDMO) based in Reading, UK. The acquisition strengthens and expands Quotient’s formulation and manufacturing services footprint in the UK, and further supports the growth of Quotient’s Translational Pharmaceutics® platform, following the acquisitions of SeaView Research and QS Pharma in February 2017.

Pharmaterials has a significant track record in supporting the development of small molecule drug products for oral and inhaled delivery. The company’s portfolio of services spans the characterisation and optimisation of drug substance physical forms, the development of preclinical and clinical formulations, through to clinical trial manufacturing and subsequent global drug product supply. The business was founded in 2000 and is located in a 48,000 square feet facility that houses 13 GMP manufacturing suites, with space for future expansion.

Mark Egerton, Chief Executive Officer, Quotient, stated: “The acquisition of Pharmaterials strengthens Quotient’s service portfolio from preclinical formulation development through to commercial manufacturing. The addition expands Quotient’s global CDMO services with added capacity and capabilities to better serve our clients’ needs.”

With over 700 employees, six operating sites across the US and UK and a 30-year track record for quality services, Quotient is focused on delivering an innovative portfolio of services that are proven to shorten development timelines, reduce associated costs and accelerate the delivery of new medicines to patients globally.

– Ends –

Further information:
GHO Capital Partners LLP
T +44 20 3700 7440
E IR@ghocapital.com

Katie Odgaard
Zyme Communications
T +44 (0)7787 502 947
E katie.odgaard@zymecommunications.com

Robin Bodicat
Quotient Sciences
T +44 (0)115 931 5102
E robin.bodicat@quotientsciences.com

About GHO Capital
Global Healthcare Opportunities, or GHO Capital Partners LLP, is a specialist healthcare investment adviser based in London. Our vision is to apply global capabilities and perspectives to build a world-class healthcare specialist private equity firm by recognising and seizing the highly attractive and underpenetrated European market opportunity. We have a powerful combination of transaction, investment and industry skills which sets us apart from traditional private equity firms. For further information, please visit www.ghocapital.com.

About Quotient Sciences
Quotient Sciences, a global pharmaceutical development, clinical pharmacology, and clinical and commercial manufacturing organisation, delivers innovative, customised solutions for pharmaceutical and biotech customers through both individual and integrated services. Its Translational Pharmaceutics® platform integrates formulation development, real-time adaptive GMP manufacturing and clinical research for the continuous improvement of drug development programs, and is proven to accelerate timelines and reduce cost. For further information, please visit www.quotientsciences.com.

About Pharmaterials
Pharmaterials Ltd. is a contract development and manufacturing organisation, specialising in the drug substance screening, formulation development and manufacturing of preclinical and early phase oral and inhaled dosage forms. For more information, visit www.pharmaterials.co.uk.

EmailPrintShare
News